RPE65 and retinal degeneration: This is especially relevant given the approved gene therapy, other on-going gene therapy trials (NCT02781480), and also that all previous RPE65-RD gene therapy trials noted retinal thinning following subretinal injection, which suggested continued retinal degeneration despite intervention.42